Ixekizumab

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Ixekizumab
Monoclonal antibody
Type Whole antibody
Source Humanized
Target IL-17a
Clinical data
Trade names Taltz
AHFS/Drugs.com entry
Legal status
Identifiers
CAS Number 1143503-69-8 N
ATC code none
Chemical data
Formula C6492H10012N1728O2028S46
Molecular mass 146.2 kg/mol
 NYesY (what is this?)  (verify)

Ixekizumab is a humanized monoclonal antibody for the treatment of autoimmune diseases.[1] It was approved by the FDA on 22 March 2016 for the treatment of plaque psoriasis, under the trade name Taltz,[2] and by the European Medicines Agency on 25 April 2016 under the same trade name.[3] Clinical trials included a Phase II clinical trial of patients with moderate to severe psoriasis,[4] and a Phase III open-label trial as of November 2013.[5]

Ixekizumab was developed by Eli Lilly and Co.

Mechanism of action

Ixekizumab binds to interleukin 17 and blocks its action. This mechanism is similar to that of another anti-psoriasis antibody, brodalumab, which binds to the interleukin-17 receptor.[4]

References

  1. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  3. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  4. ↑ 4.0 4.1 Lua error in package.lua at line 80: module 'strict' not found.
  5. ↑ Clinical trial number NCT01624233 for "A Study in Japanese Participants With Moderate-to-Severe Psoriasis" at ClinicalTrials.gov


<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.
Retrieved from "https://infogalactic.com/w/index.php?title=Ixekizumab&oldid=722986230"